Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals

Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry

(2016) Alexander F. Hoffman et al.   ACS Chemical Neuroscience

Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration

(2016) Shawn P. Alter et al.   EXPERIMENTAL NEUROLOGY

Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity

(2015) Kelly M. Lohr et al.   ACS Chemical Neuroscience

Changes in Neuronal Dopamine Homeostasis following 1-Methyl-4-phenylpyridinium (MPP+) Exposure

(2015) Se Joon Choi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias

(2015) Perdita Cheshire et al.   MOVEMENT DISORDERS

Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits

(2015) S.T. Masoud et al.   NEUROBIOLOGY OF DISEASE

Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum

(2014) C. Pifl et al.   JOURNAL OF NEUROSCIENCE

Presynaptic effects of levodopa and their possible role in dyskinesia

(2014) Eugene V. Mosharov et al.   MOVEMENT DISORDERS

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

(2014) Kelly M. Lohr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

(2014) M. Angela Cenci   Frontiers in Neurology

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease

(2013) Laura Brighina et al.   NEUROBIOLOGY OF AGING

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus

(2013) Tonya N. Taylor et al.   NEUROPHARMACOLOGY

Brain Dopamine–Serotonin Vesicular Transport Disease and Its Treatment

(2013) Jennifer J. Rilstone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimizing the Temporal Resolution of Fast-Scan Cyclic Voltammetry

(2012) Brian M. Kile et al.   ACS Chemical Neuroscience

Occupational pesticide exposure and screening tests for neurodegenerative disease among an elderly population in Costa Rica

(2012) K. Steenland et al.   ENVIRONMENTAL RESEARCH

Parkinson's disease and the environment: Beyond pesticides

(2012) W. Michael Caudle et al.   NEUROTOXICOLOGY

Association between polychlorinated biphenyls and Parkinson's disease neuropathology

(2012) Jaime M. Hatcher-Martin et al.   NEUROTOXICOLOGY

Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration

(2011) A.C. Meyer et al.   NEUROPHARMACOLOGY

Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments

(2011) Jill R. Crittenden et al.   Frontiers in Neuroanatomy

Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3

(2009) L. A. Egana et al.   JOURNAL OF NEUROSCIENCE

Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity

(2009) T. N. Taylor et al.   JOURNAL OF NEUROSCIENCE

Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

(2009) Thomas S. Guillot et al.   MOLECULAR NEUROBIOLOGY

Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis

(2008) Thomas S. Guillot et al.   JOURNAL OF NEUROCHEMISTRY

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE